CurrentEndo
Get Weekly

General medical journalCurrentEndo coverage

The Lancet

What CurrentEndo has captured from this journal. The coverage figures describe CurrentEndo's coverage, not the journal's output. Figures as of 14 November 2026.

CurrentEndo holds 60 Briefs from The Lancet, most often randomized controlled trials and meta-analyses.

Recent
5 Briefs
past 90 days
Archive
60 Briefs
research published Oct 2023 – today and Jan–Jun 2023
Editorial
–
no Weekly issue published yet

Topics

Evidence types

Shares are of the 60 Briefs CurrentEndo has covered from Lancet, by primary topic and study type; a Brief without a primary topic is in no topic row.

Publication activity

Latest from The Lancet

All coverage, newest first

  1. Lancet

    Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial

    Randomized controlled trialObesity

  2. Lancet

    Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial

    Randomized controlled trialObesity

  3. Lancet

    Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial

    Randomized controlled trialT2D & other

  4. Lancet

    Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial

    Randomized controlled trialObesity

  5. Lancet

    Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial

    Randomized controlled trial

  6. Lancet

    Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial

    Randomized controlled trialT2D & other

  7. Lancet

    Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial

    Randomized controlled trialT2D & other

  8. Lancet

    [177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial

    Randomized controlled trialEndocrine cancer

  9. Lancet

    Metabolic traits in obesity and normal BMI in industrialised countries: a multi-country analysis of national population-based studies

    Meta-analysisObesity

  10. Lancet

    The impact of Chile's multipronged food labelling and advertising law on early childhood excess weight: a cohort difference-in-differences study

    Cohort studyObesity

  11. Lancet

    Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial

    Randomized controlled trialT2D & other

  12. Lancet

    Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial

    Randomized controlled trialObesity

  13. Lancet

    Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial

    Randomized controlled trialT2D & other

  14. Lancet

    Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

    Randomized controlled trialT2D & other

  15. Lancet

    Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial

    Randomized controlled trialT2D & other

  16. Lancet

    Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial

    Randomized controlled trialObesity

  17. Lancet

    Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process

    Guideline or statementReproductive endocrine

  18. Lancet

    Integrated community-based versus facility-based care for people with HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-COMM): an open-label, multicountry, cluster-randomised trial

    Randomized controlled trialT2D & other

  19. Lancet

    Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial

    Randomized controlled trial

  20. Lancet

    Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial

    Randomized controlled trialT2D & other

  21. Lancet

    Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial

    Randomized controlled trialT1D

  22. Lancet

    Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial

    Randomized controlled trialObesity

  23. Lancet

    Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial

    Secondary analysisObesity

  24. Lancet

    Minimum effective low dose of antithymocyte globulin in people aged 5–25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial

    Randomized controlled trialT1D

  25. Lancet

    Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial

    Randomized controlled trialT2D & other

  26. Lancet

    Parent-focused behavioural interventions for the prevention of early childhood obesity (TOPCHILD): a systematic review and individual participant data meta-analysis

    Meta-analysisObesity

  27. Lancet

    Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial

    Randomized controlled trialT2D & other

  28. Lancet

    Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial

    Randomized controlled trialT2D & other

  29. Lancet

    Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study

    Randomized controlled trialObesity

  30. Lancet

    Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial

    Randomized controlled trialObesity

  31. Lancet

    Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN): a randomised, multicentre, non-inferiority trial

    Randomized controlled trialEndocrine cancer

  32. Lancet

    Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial

    Randomized controlled trialComplications

  33. Lancet

    Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021

    Research articleObesity

  34. Lancet

    Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021

    Research articleObesity

  35. Lancet

    A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study

    Diagnostic or prognostic studyT2D & other

  36. Lancet

    National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990–2021, and forecasts up to 2050

    Research articleObesity

  37. Lancet

    Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants

    Meta-analysisT2D & other

  38. Lancet

    Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial

    Randomized controlled trialT1D

  39. Lancet

    Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

    Secondary analysisObesity

  40. Lancet

    [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

    Randomized controlled trialEndocrine cancer

All 60 Briefs in ExploreShowing the 40 most recently published